Canaccord Says Sell NuVasive On Deal Speculation Rally, Buy Smith & Nephew

Canaccord Genuity analyst Kyle Rose advises investors in the near-term to sell NuVasive (NUVA) into the deal-related strength and add to positions in Smith & Nephew (SNN) on the acquisition speculation selloff.

Image result for NuVasive

The analyst does not find a potential of NuVasive acquisition by Smith & Nephew "to be compelling". A deal could be disruptive to Smith & Nephew's turnaround in both commercial performance and investor sentiment, Rose told investors earlier in a research note. The analyst admits to being caught off guard by Friday's Financial Times report of deal talks. Not by the idea of M&A speculation, but rather the idea of Smith & Nephew "choosing to utilize nearly all of its acquisition bandwidth on a spine acquisition," says Rose.

He believes the spine market "doesn't seem to check the right 'growth' boxes." Further, spine deals are "notoriously challenging" given the importance of the distributor/customer relationship and disruption caused in the commercial channels during integration, he adds. Should the talks progress, Rose believes it would take at least $60 per share, or a 21% premium to Friday's closing price, for NuVasive to seriously consider a deal. Shares of NuVasive are up 15%, or $7.64, to $57.19 in midday trading while Smith & Nephew is down 4% to $38.43. From a long-term perspective, the analyst says he would maintain Buy ratings on both stocks should the deal were not to be ultimately consummated.

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.